Sequoia Capital, founded in 1972 and based in Menlo Park, California, is a prominent venture capital firm that invests in early to growth stage companies across various sectors, including technology, healthcare, financial services, and consumer services. The firm specializes in supporting startups and emerging growth companies, typically investing between $100,000 and $1 million in seed companies, $1 million to $10 million in early ventures, and $10 million to $100 million in growth investments. Sequoia Capital operates globally, with a presence in regions such as Israel, China, and Southeast Asia, and has built a diverse portfolio that includes notable companies like Airbnb, Alibaba, and JD.com. The firm emphasizes a partnership approach with entrepreneurs, leveraging decades of experience to guide them from initial concept through to public offering and beyond.
PhaBuilder is a technology company specializing in synthetic biology, particularly in the transformation and engineering of halophilic microbes. Founded in February 2021 by Professor Guoqiang Chen, the company employs advanced methodologies to develop high-value products such as biodegradable polyhydroxyalkanoates (PHA), ectoine for pharmaceuticals, and cadaverine for nylon production. PhaBuilder is currently constructing two PHA production facilities, one in Beijing and another in Yichang, with plans to establish three to five large-scale production sites across China within five years. The company has successfully completed two rounds of financing, securing approximately 300 million yuan from notable investors. PhaBuilder aims to integrate synthetic biotechnology into various aspects of daily life and enhance the intelligent biological manufacturing sector, aspiring to fulfill its mission of utilizing microbes to foster a sustainable and eco-friendly future.
ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
Full-Life Technologies Limited is a global company specializing in RadioTherapeutics, with its headquarters in Shanghai, China, and operations extending to Europe. The firm focuses on targeted cancer therapy services within the radiotherapy field, aiming to enhance treatment outcomes for cancer patients. Full-Life is dedicated to advancing nuclear medicine through innovative research in radiopharmaceuticals, which supports healthcare providers in delivering effective cancer treatments.
Bioforany
Venture Round in 2022
Bioforany is a biocatalyst manufacturer specializing in biocatalysts development and sales. Bioforany supply's low-carbon products to consumers in the domains of pharmaceutical intermediates, traditional Chinese medicine decoction components, functional food, animal nutrition, daily chemical care, plant protection, and renewable materials.
Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company's software helps pharmaceutical companies accelerate the movement of new drugs in the pipeline through optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
PhaBuilder is a technology company specializing in synthetic biology, particularly in the transformation and engineering of halophilic microbes. Founded in February 2021 by Professor Guoqiang Chen, the company employs advanced methodologies to develop high-value products such as biodegradable polyhydroxyalkanoates (PHA), ectoine for pharmaceuticals, and cadaverine for nylon production. PhaBuilder is currently constructing two PHA production facilities, one in Beijing and another in Yichang, with plans to establish three to five large-scale production sites across China within five years. The company has successfully completed two rounds of financing, securing approximately 300 million yuan from notable investors. PhaBuilder aims to integrate synthetic biotechnology into various aspects of daily life and enhance the intelligent biological manufacturing sector, aspiring to fulfill its mission of utilizing microbes to foster a sustainable and eco-friendly future.
Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., founded in 2012 and located in Zhengjiawu, China, specializes in researching and developing innovative drugs for metabolic diseases and breast cancer. The company focuses on addressing conditions such as Non-Alcoholic SteatoHepatitis (NASH), gout, diabetes, and colon cancers. By concentrating on metabolism and inflammation, Atom Bioscience aims to provide more effective treatment options for patients suffering from these ailments, enhancing the quality of care in the healthcare sector.
Amador Bioscience, a contract research organization (CRO) that provides global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies.
Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company's software helps pharmaceutical companies accelerate the movement of new drugs in the pipeline through optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.
ABclonal Inc. provides biological research agents and services. Its products include next generation sequencing lib preparation kits, molecular biology products, catalog antibody products, catalog proteins, ELISA kits, and western blot tools and reagents. The company also offers peptide, antibody, and protein services. It provides its products through distributors in Europe, Asia, North America, and Oceania. The company was incorporated in 2016 and is based in Woburn, Massachusetts.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.
ComGen Pharma is a biotechnology company that specializes in the research and development of innovative therapeutic drugs targeting the complement system. The company aims to create effective immunotherapies for autoimmune diseases and tumors by focusing on new and key targets within this biological pathway. Recently, ComGen Pharma secured nearly 100 million yuan in financing, which will primarily support phase I clinical trials for its complement inhibitors, advance its drug pipeline, and enhance its innovative drug research and development platform. The financing round was led by prominent investors, including Sequoia China and Yahui Investment, with additional support from Fuchuang Investment and Renyou Investment.
ShouTi specializes in the discovery and development of drugs against a type of targets called GPCR. The company develops drugs focused on novel small molecules for multiple unmet medical needs. ShouTi is currently operating in Stealth mode.
Amador Bioscience, a contract research organization (CRO) that provides global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
Joyo Pharma
Series B in 2021
Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.
Westlake Therapeutics is a biopharmaceutical company based in Hangzhou, China, founded in 2019. The company specializes in cell therapy, focusing on developing engineered Red Blood Cells (RBC) through its REDx platform. This innovative technology aims to treat a wide range of human diseases, including cancers, immunological and metabolic disorders, and rare diseases. By utilizing genetic engineering techniques on hematopoietic stem and progenitor cells sourced from peripheral blood, bone marrow, or cord blood, Westlake Therapeutics seeks to provide personalized and effective treatment options for patients, advancing the field of cellular medicine.
Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.
ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.
Bexion is a software-based species design, biomanufacturing and biotechnology ecological company. Aiming at software-engineered species design - giving full play to the self-replication and scalability of biological software and hardware, establishing a modular genome code base, a rapid iteration platform, and completely unlocking the productivity of the biological industry. Beisheng's products are artificial species libraries and related pipelines that meet specific industrial purposes, focusing on the research and development of food, daily chemicals, and protein drugs.
MoonBiotech is a Guangzhou-based healthcare startup that focuses on the development and research of microbe-based bioactive products for diverse applications. The company specializes in creating and screening high-quality microbial ingredients and fermentation products, catering to the needs of various industries such as biological agriculture, environmental governance, health food, and biomedicine. By providing valuable microbiological resources, MoonBiotech aims to address the increasing demand for innovative solutions in these sectors.
InSilico Medicine, Inc. is an artificial intelligence company focused on drug discovery, biomarker development, and aging research. Founded in 2014 and headquartered in Baltimore, Maryland, the company employs advanced AI technologies, including deep learning and generative adversarial networks, to create novel molecular structures for diseases with known and unknown targets. Its comprehensive platform covers all stages of drug development, from discovery to clinical trials. Key initiatives include Pharma.AI, which offers machine learning services to various industries, and Young.AI, which predicts biological age. InSilico Medicine also engages in internal drug discovery programs targeting conditions such as cancer, Parkinson's Disease, and age-related disorders. Additionally, the company has partnered with Life Extension to develop nutraceutical products using its bioinformatics and deep learning techniques. Through its innovative solutions, InSilico Medicine aims to enhance personalized healthcare and mitigate the effects of aging.
HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.
Analytical Biosciences focuses on the development of single-cell genome technologies to enhance the understanding and treatment of human diseases. By collaborating with medical research institutions, hospitals, and pharmaceutical companies, the company leverages single-cell genomics and bioinformatics to create detailed maps of diseases. This approach allows for large-scale systematic disease mapping and the mining of extensive data sets, which aids partners in identifying new therapeutic targets and formulating innovative treatment strategies. Analytical Biosciences employs high-resolution databases and advanced data analytics to facilitate the discovery and validation of novel cellular targets and biomarkers, ultimately contributing to the development of next-generation therapeutics and diagnostics.
Phanes Therapeutics, Inc. is a biotechnology company based in San Diego, California, established in 2016. It specializes in the discovery and development of therapeutics aimed at treating solid tumors and eye diseases. The company's portfolio includes a monoclonal antibody designed for solid tumors and various ophthalmic conditions such as age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Additionally, Phanes Therapeutics is developing a bispecific antibody targeting small cell lung cancer. With a focus on scientific innovation, the company strives to create advanced therapeutic options that enhance patient care and improve lives worldwide.
Developer and researcher of innovative drugs for vision treatment designed to cure topical diseases. The company focuses on delivering new therapies to millions of patients living with chronic ocular or dermal inflammatory diseases by combining world-class expertise and promising drug targets, providing best-in-class therapeutics and pharmaceuticals for the treatment of dry eye syndromes and atopic dermatitis.
Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform encompasses a range of integrated applications that enable scientists to design, share, and document experiments efficiently. Key offerings include an electronic lab notebook for experiment documentation, a biological registration system for managing inventory like plasmids and antibodies, and analytical tools for visualizing and collaborating on structured data. Benchling's software supports cutting-edge research techniques such as CRISPR and CAR-T immunotherapy, facilitating advancements in biotherapeutics, biofuels, and biomaterials. The company's solutions are utilized by researchers in biotech and pharmaceutical companies, as well as academic and government labs, streamlining workflows and enhancing collaboration across various research projects. Founded in 2012, Benchling is headquartered in San Francisco, California.
Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.
ABclonal Inc. provides biological research agents and services. Its products include next generation sequencing lib preparation kits, molecular biology products, catalog antibody products, catalog proteins, ELISA kits, and western blot tools and reagents. The company also offers peptide, antibody, and protein services. It provides its products through distributors in Europe, Asia, North America, and Oceania. The company was incorporated in 2016 and is based in Woburn, Massachusetts.
Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.
Novotech is Australia’s largest independent CRO. The Australian Head Office is in Sydney, with regional offices in Melbourne and Brisbane - providing easy access to the most important population centers in Australia. Supported by regional staff across the country and in New Zealand, our coverage of the Australia/New Zealand region is comprehensive. With Asian services launched in 2007, Novotech’s operations provide access to the most dynamic and fast growing clinical research hubs in the region.
Visen Pharmaceuticals is a biotechnology company dedicated to the development and commercialization of innovative endocrine drugs. The company aims to address significant unmet medical needs for patients in Greater China, focusing specifically on endocrine treatment solutions. By leveraging its expertise in biotechnology, Visen Pharmaceuticals seeks to improve patient outcomes through the creation of effective therapies in the field of endocrinology.
dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
D3 Bio Inc. is a biotechnology company founded in 2020 and based in China. It specializes in the development and registration of innovative medicines, primarily focusing on oncology and immunology. The company adopts a unique approach to medicine development by first identifying significant unmet patient and market needs, particularly in areas where current treatments are inadequate. This understanding informs their research and guides the selection of appropriate scientific and technological methods to define their drug development strategy. Through this differentiated approach, D3 Bio aims to address critical health challenges and improve clinical outcomes for patients.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
Orasis Pharmaceuticals Ltd is focused on developing innovative treatments for presbyopia, a common age-related vision condition. Founded in 2015 and based in Herzliya, Israel, the company has developed CSF-1, a corrective eye drop designed to improve near visual acuity through pupil modulation. This product aims to enhance the quality of life for individuals with presbyopia by alleviating the need for reading glasses. CSF-1 repurposes existing, well-studied molecules to ensure its effectiveness while prioritizing safety, comfort, and ease of use for patients. By providing a noninvasive treatment option, Orasis Pharmaceuticals offers a promising solution for those struggling with the symptoms of presbyopia.
LP Pharmaceuticals (Xiamen) Co., Ltd., located in Xiamen Biomedical Industry Base which formulates and manufactures pharmaceuticals with enhanced delivery properties. The company was founded in 2012 by a group of scientists and business professionals with extensive experience in the US and Chinese pharmaceutical industry. Proprietary delivery platforms include mucosal and oral controlled release. Therapeutic areas currently concern central nervous system, digestive system, cardiovascular, cancer and AIDS.
Dizal Pharmaceutical is a research-focused biotechnology company involved in the discovery, development, and commercialization of innovative medicines. The company specializes in creating first-in-class and best-in-class therapeutic solutions, emphasizing cutting-edge research and development. In addition to its drug development efforts, Dizal is also engaged in the production and sales of these innovative treatments, aiming to improve patient outcomes through advanced pharmaceutical solutions.
Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., founded in 2012 and located in Zhengjiawu, China, specializes in researching and developing innovative drugs for metabolic diseases and breast cancer. The company focuses on addressing conditions such as Non-Alcoholic SteatoHepatitis (NASH), gout, diabetes, and colon cancers. By concentrating on metabolism and inflammation, Atom Bioscience aims to provide more effective treatment options for patients suffering from these ailments, enhancing the quality of care in the healthcare sector.
Virtual is a developer of prescription digital therapeutics platform intended to help mental health treatment. The company's tool adheres to strict compliance with FDA quality management standards and also is put through rigorous research trials and in certain cases is paired with existing pharmacological treatments, as well as uses virtual reality to administer VR exposure therapy, assign CBT assessments or exercises and track patient progress, enabling patients to overcome anxiety, phobia and obsessive-compulsive disorder easily.
Buymed operates a digital pharmaceuticals distribution platform in Vietnam, known as Thuocsi.vn. Founded in 2018 and based in Ho Chi Minh City, the platform supplies a wide range of healthcare products, including medicines, cosmetics, medical devices, and supplements. It serves over 1,000 pharmacies and clinics across the country, offering detailed product information such as pricing and active ingredients. Additionally, Thuocsi.vn features a communication network that provides important updates, including product recalls. The company is recognized as a successful startup in the medical technology sector, attracting young talent eager to integrate advanced technology into healthcare solutions.
Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.
HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.
Yaoyanshe is a healthcare company based in Shanghai, China, specializing in the development of an application that facilitates value sharing and trading in the pharmaceutical research and development sector. Founded in 2012, the company provides a platform that integrates and shares clinical research-based data, offering medical professionals access to comprehensive pharmaceutical research information. Additionally, it delivers patients the latest updates on treatment options and drugs, while also providing industry personnel with credit assessments, research project competition analysis, and evaluations of sponsor projects. This approach aims to enhance accessibility to extensive healthcare-related data for both professionals and patients.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Pendulum Therapeutics Inc., a microbiome company, produces microbiome-targeted medical probiotics. It offers Pendulum Glucose Control, a medical probiotic for the dietary management of type 2 diabetes. The company also develops prebiotics to help feed the probiotic strains. It sells its products online. Pendulum Therapeutics Inc. was formerly known as Whole Biome Inc. and changed its name to Pendulum Therapeutics Inc. in July 2019. The company was incorporated in 2012 and is based in San Francisco, California.
Cullgen Inc. is a biopharmaceutical company based in San Diego, California, established in 2018. The company focuses on developing innovative new chemical entities (NCEs) aimed at treating diseases that currently lack effective therapeutic options. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins. This approach is particularly significant for addressing cancer, inflammatory, and autoimmune diseases, including targets that have been deemed undruggable. By providing novel therapeutic strategies, Cullgen aims to enhance drug discovery and offer new avenues for treating debilitating conditions.
BridgeBio is a biotechnology company dedicated to the discovery, development, and delivery of medicines for genetic diseases. The company has a diverse pipeline of 20 development programs, which range from early discovery to late-stage clinical trials. Among its notable candidates are BBP-265, an oral small molecule targeting transthyretin amyloidosis currently in Phase 3 trials, and infigratinib, a selective tyrosine kinase inhibitor aimed at treating FGFR-driven cancers and achondroplasia. Additionally, BridgeBio is developing BBP-631, a preclinical gene therapy for congenital adrenal hyperplasia, and BBP-454, a program focused on small molecule inhibitors for KRAS-driven cancers. The company collaborates with several prestigious institutions, including Stanford University and Johns Hopkins University, to enhance its research and development efforts. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio aims to accelerate the development of therapies for Mendelian diseases, genetic dermatology, and oncology.
BrightGene Bio-medical technology Co.,Ltd., is a leading Chinese biopharmaceutical company in small molecules and nucleotide drugs areas. Advised by China-based venture capital fund Laurel Venture Capital, BrightGene invests in all stage therapeutics and innovations.
Phrase Health, Inc., founded in 2018 and based in Philadelphia, Pennsylvania, offers software solutions tailored for the healthcare sector. The company's platform is designed to help hospitals monitor and analyze the information provided to doctors and nurses at the point of care. By facilitating workflow management, Phrase Health enables healthcare professionals to identify actionable insights and supports data-driven process improvements. The software aids in decision-making and enhances user interaction, allowing for better coordination of strategic initiatives within healthcare environments.
Developer, manufacturer and retailer of beauty and personal care products. The company has several consumer product segments, such as COCOVEL, MARTIN, Clearsoft, BARBER, Man Zhi Tang, HOF, Kangpai, Dr.Kawamoto, molimood and White Essence, providing customers with perfumes, hair care, skin care, beauty, baby care and other personal care products.
Berkeley Lights, Inc. is a digital cell biology company based in Emeryville, California, established in 2011. The company focuses on accelerating the development and commercialization of biotherapeutics and other cell-based products through its integrated platform. This platform includes proprietary consumables, such as OptoSelect chips and reagent kits, along with automation systems and workflow software. Utilizing micro-droplet technology, Berkeley Lights offers research and development services that transform how scientists study cell interactions, significantly enhancing the efficiency of cellular therapies. Their solutions cater to various sectors, including biotherapeutic discovery, cellular therapy manufacturing, synthetic biology, and agricultural biotechnology, helping clients meet the increasing demands of cell-based processes.
Beijing Deep Intelligent Pharma Technology Co., Ltd. specializes in leveraging artificial intelligence and blockchain technology to enhance drug discovery, development, and medical affairs for pharmaceutical companies. Founded in 2017 and based in Beijing, the company offers a range of products, including a multi-language medical machine translation engine, intelligent pharmacovigilance for risk management, and tools for creating multilingual educational materials. Deep Intelligent Pharma also provides AI-enabled solutions for medical writing, document review, and quality control, as well as a patient search ecosystem to facilitate medical and clinical research. Additionally, the company offers intelligent regulatory affairs solutions to streamline drug research and development processes. Operating globally, including in China, the United States, and Japan, Deep Intelligent Pharma aims to improve the efficiency and quality of the pharmaceutical development lifecycle.
Orasis Pharmaceuticals Ltd is focused on developing innovative treatments for presbyopia, a common age-related vision condition. Founded in 2015 and based in Herzliya, Israel, the company has developed CSF-1, a corrective eye drop designed to improve near visual acuity through pupil modulation. This product aims to enhance the quality of life for individuals with presbyopia by alleviating the need for reading glasses. CSF-1 repurposes existing, well-studied molecules to ensure its effectiveness while prioritizing safety, comfort, and ease of use for patients. By providing a noninvasive treatment option, Orasis Pharmaceuticals offers a promising solution for those struggling with the symptoms of presbyopia.
Cortexyme, Inc. is a clinical stage biopharmaceutical company based in South San Francisco, California, focused on developing therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company's lead drug candidate, COR388, is an orally administered small molecule designed to inhibit gingipain, which is linked to neurodegeneration. Currently in Phase II/III clinical trials, COR388 targets patients with mild to moderate Alzheimer's disease. Cortexyme's research is grounded in a novel theory linking a specific, undisclosed pathogen to the progression of neurodegenerative conditions, a hypothesis supported by various animal model studies. The company was founded in 2012 and continues to advance its therapeutic candidates through preclinical and clinical development phases.
Eden Biologics is a biopharmaceutical company founded in 2012 and headquartered in Zhubei City, Taiwan. The company specializes in contract development and manufacturing services aimed at accelerating the development programs of its partners in the biopharmaceutical sector. It offers a comprehensive range of services, including cell line development, process development, analytical services, formulation development, and cGMP manufacturing. Eden Biologics is committed to making high-quality biologic medicines affordable and accessible by leveraging advanced process and engineering technologies that simplify and reduce the costs associated with mammalian cell culture manufacturing. The company operates state-of-the-art manufacturing facilities in Asia, adhering to US, EU, and ICH cGMP regulations, and is led by a team of experienced professionals with backgrounds in leading biopharmaceutical companies.
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.
HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.
CStone Pharmaceuticals is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the development and commercialization of innovative immuno-oncology and molecularly targeted drugs aimed at addressing unmet medical needs in cancer treatment. Founded in 2015, the company has a diverse product pipeline that includes late-stage clinical candidates such as CS1001, a monoclonal antibody targeting programmed death ligand 1, and CS1003, targeting programmed death receptor. Other notable products include ivosidenib, avapritinib, and Pralsetinib, which are designed for various types of cancer, including gastrointestinal stromal tumors and medullary thyroid cancer. CStone has established strategic partnerships and collaborations, including agreements with Numab Therapeutics AG and Bayer HealthCare LLC, to enhance its research and development efforts. The company aims to provide effective therapeutic options tailored to the needs of cancer patients both in China and globally.
XtalPi Inc. is a pharmaceutical technology company founded in 2014 and headquartered in Cambridge, Massachusetts, with additional offices in China. The company specializes in leveraging artificial intelligence and advanced computing to accelerate drug development. Its offerings include XtalForc, a visual force field calculation software; XtalVision, a tool for crystal structure prediction; and Renova, which supports AI-driven research and development. XtalPi provides a range of services such as crystal structure prediction and determination, solid state testing and analysis, crystallization process development, and small molecule drug design. By collaborating with pharmaceutical companies, XtalPi uses its predictive algorithms to facilitate the development of new drugs and the creation of patents, enhancing the efficiency of the drug discovery process.
Vaccitech Limited is a biotechnology company based in Oxford, United Kingdom, that focuses on researching and developing T cell immunotherapeutic products and vaccines. Established in 2016 as a spin-out from the University of Oxford’s Jenner Institute, the company specializes in viral vector vaccines designed to address significant health challenges, including hepatitis B, human papillomavirus, and prostate cancer. Vaccitech utilizes advanced chimpanzee adenovirus technology to elicit robust T-cell responses, fostering lasting cell-mediated immunity. The company has progressed its assets into clinical trials, showing promising initial results. Upcoming studies include a phase IIB efficacy trial for a universal influenza vaccine targeting individuals aged 65 and older, as well as an extended phase I trial for prostate cancer treatment, reflecting Vaccitech's commitment to advancing innovative therapeutic solutions.
EOC Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. The company specializes in developing, manufacturing, and commercializing innovative oncology products, utilizing a licensing model to enhance its product pipeline. EOC partners with global biopharmaceutical firms to integrate their molecules into its local manufacturing and regulatory frameworks. The company currently has a pipeline of seven novel products, four of which have received Class I innovative drug approvals and are undergoing clinical studies in China. EOC operates an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City, and maintains offices in major cities, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team experienced in pharmaceutical research and development, EOC aims to position itself as a leader in oncology innovation within China.
Provider of on demand drug delivery platform intended to create a better experience for patients at a lower price. Nimble partners with pharmacies nationwide to provide prescription delivery, as well as a mobile app for patients to manage and review prescriptions/orders from their phone.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Vets First Choice provides veterinary practices with an online pharmacy and home delivery services. It partners with veterinarians to create insight into gaps in patient care and offer professionalized pro-active prescription management to drive client engagement and improve compliance. The company was founded by Ben Shaw in 2010 and is based in Portland, Maine.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Vivace Therapeutics, Inc. is a small molecule discovery and development company focused on creating innovative cancer therapeutics by targeting the Hippo pathway, which plays a critical role in tissue regeneration and organ development. Founded in 2014, the company is based in San Mateo, California, and operates with a commitment to advancing novel therapies that can improve outcomes for cancer patients. Vivace Therapeutics emphasizes a capital-efficient and modality-indifferent approach, collaborating with leading academic laboratories to leverage cutting-edge research. Its experienced management team and top-tier scientists aim to develop treatments that can be used independently or in combination with existing therapies, ultimately striving to enhance the lives of individuals affected by cancer.
Virtual is a developer of prescription digital therapeutics platform intended to help mental health treatment. The company's tool adheres to strict compliance with FDA quality management standards and also is put through rigorous research trials and in certain cases is paired with existing pharmacological treatments, as well as uses virtual reality to administer VR exposure therapy, assign CBT assessments or exercises and track patient progress, enabling patients to overcome anxiety, phobia and obsessive-compulsive disorder easily.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.
Orasis Pharmaceuticals Ltd is focused on developing innovative treatments for presbyopia, a common age-related vision condition. Founded in 2015 and based in Herzliya, Israel, the company has developed CSF-1, a corrective eye drop designed to improve near visual acuity through pupil modulation. This product aims to enhance the quality of life for individuals with presbyopia by alleviating the need for reading glasses. CSF-1 repurposes existing, well-studied molecules to ensure its effectiveness while prioritizing safety, comfort, and ease of use for patients. By providing a noninvasive treatment option, Orasis Pharmaceuticals offers a promising solution for those struggling with the symptoms of presbyopia.
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.
Provider of on demand drug delivery platform intended to create a better experience for patients at a lower price. Nimble partners with pharmacies nationwide to provide prescription delivery, as well as a mobile app for patients to manage and review prescriptions/orders from their phone.
Berkeley Lights, Inc. is a digital cell biology company based in Emeryville, California, established in 2011. The company focuses on accelerating the development and commercialization of biotherapeutics and other cell-based products through its integrated platform. This platform includes proprietary consumables, such as OptoSelect chips and reagent kits, along with automation systems and workflow software. Utilizing micro-droplet technology, Berkeley Lights offers research and development services that transform how scientists study cell interactions, significantly enhancing the efficiency of cellular therapies. Their solutions cater to various sectors, including biotherapeutic discovery, cellular therapy manufacturing, synthetic biology, and agricultural biotechnology, helping clients meet the increasing demands of cell-based processes.
Stemcentrx is a biotechnology company focused on developing innovative therapies aimed at curing and significantly improving survival rates for cancer patients. Founded in 2008 by Brian Slingerland and Scott J. Dylla, the company is headquartered in South San Francisco, California. Stemcentrx specializes in disease-specific treatments designed to target tumors effectively at their roots. As of June 1, 2016, Stemcentrx operates as a subsidiary of AbbVie, further enhancing its capabilities in cancer research and treatment development.
Celon Laboratories Limited engages in developing, manufacturing, and marketing pharmaceutical products in the areas of oncology, anti-infective, and critical care markets. It produces un-coated and coated tablets, capsules, ampoules, vials, pre-filled syringes, and emulsion injections. The company also provides contract research manufacturing services that include formulation development, lyophilization cycle development, QC testing, stability studies, and regulatory support services. It serves customers in the Asia Pacific, Africa, Latin America, CIS countries, and Eastern Europe. The company was incorporated in 2001 and is based in Hyderabad, India.
Akumentis Healthcare Ltd manufactures pharmaceutical products. The company was founded in 2010 and is based in Thane, India. Akumentis Healthcare Ltd operates as a subsidiary of Akums Drugs and Pharmaceuticals Ltd.
La Renon" is created out of passion to become a global healthcare company by offering World-class quality pharmaceutical products and services for various critical illnesses and diseases."La Renon" is founded and managed by a group of professionals of varied domains of healthcare industry itself who have got vast experience with unmatched expertise to achieve the above said objective. The company's focus is on continuous value addition to its business model, to make it an unparallel platform for their every stakeholder.
Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
ECPM is a medical device company focused on designing and commercializing a platform of products and services for gastrointestinal caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology, and imaging systems. Its products are used in colonoscopy and procedures of the upper GI tract, including esophagogastroduodenoscopy (EGD).
The company is headquartered in Alpharetta, Georgia.
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well as evidence-based medicine and clinical pharmacology.
Curatio Healthcare (I) Pvt Ltd is a specialty dermatology company based in Chennai, India, founded in 2005. The company focuses on manufacturing a wide range of cosmetic and medical dermatology products, addressing therapy gaps in both general and specialty dermatology. Its product portfolio includes solutions for acne care, baby care, hair care, and skin care, featuring items such as tivenca for acne, Atogla for baby skin protection, and various formulations for hair and skin issues. Curatio employs extensive market research to identify the needs of dermatologists and cosmetologists, converting innovative ideas into effective products through advanced research and development capabilities. This commitment enables healthcare professionals to access reliable solutions for everyday dermatological challenges.
Zai Lab Limited is a Shanghai-based biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. The company offers several proprietary products, including Niraparib for treating solid tumors, Optune for glioblastoma multiforme, and Ripretinib for KIT and PDGFRa-driven cancers. Additionally, Zai Lab develops other investigational therapies such as REGN1979, Margetuximab, INCMGA0012, Bemarituzumab, Omadacycline, and Durlobactam. With a focus on the Chinese market, Zai Lab has established partnerships with leading global biopharmaceutical firms to enhance its drug pipeline and improve access to transformative medicines. The company leverages its expertise in drug development and favorable regulatory conditions in China, along with in-house manufacturing capabilities, to support both clinical and commercial production. Zai Lab aims to expand its operations and build a specialized commercial team to effectively market its products in China and beyond.
Stemcentrx is a biotechnology company focused on developing innovative therapies aimed at curing and significantly improving survival rates for cancer patients. Founded in 2008 by Brian Slingerland and Scott J. Dylla, the company is headquartered in South San Francisco, California. Stemcentrx specializes in disease-specific treatments designed to target tumors effectively at their roots. As of June 1, 2016, Stemcentrx operates as a subsidiary of AbbVie, further enhancing its capabilities in cancer research and treatment development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.